View Single Post
Old 04-18-2011, 02:02 AM
Conductor71's Avatar
Conductor71 Conductor71 is offline
Senior Member
 
Join Date: Jul 2009
Location: Michigan
Posts: 1,474
10 yr Member
Conductor71 Conductor71 is offline
Senior Member
Conductor71's Avatar
 
Join Date: Jul 2009
Location: Michigan
Posts: 1,474
10 yr Member
Default Melanin as a measure of progression

I know that melanin and vitamin D have something to do with it all...they are now finding that loss of melanin may be an accurate marker for charting decline. Rather sobering but beats the paper and pencil system we have now.

Mov Disord. 2011 Apr 12. doi: 10.1002/mds.23722. [Epub ahead of print]

T1-Weighted MRI shows stage-dependent substantia nigra signal loss in Parkinson's disease.

Schwarz ST, Rittman T, Gontu V, Morgan PS, Bajaj N, Auer DP.

Radiological & Imaging Sciences, University of Nottingham, Nottingham, United Kingdom.
Abstract

Depigmentation of the substantia nigra is a conspicuous pathological feature of Parkinson's disease and related to a loss of neuromelanin. Similar to melanin, neuromelanin has paramagnetic properties resulting in signal increase on specific T1-weighted magnetic resonance imaging. The aim of this study was to assess signal changes in the substantia nigra in patients with Parkinson's disease using an optimized neuromelanin-sensitive T1 scan. Ten patients with Parkinson's disease and 12 matched controls underwent high-resolution T1-weighted magnetic resonance imaging with magnetization transfer effect at 3T. The size and signal intensity of the substantia nigra pars compacta were determined as the number of pixels with signal intensity higher than background signal intensity + 3 standard deviations and regional contrast ratio. Patients were subclassified as early stage (n = 6) and late stage (n = 4) using the Unified Parkinson's Disease Rating Scale and the Hoehn and Yahr Parkinson's disease staging scale. The T1 hyperintense area in the substantia nigra was substantially smaller in patients compared with controls (-60%, P < .01), and contrast was reduced (-3%, P < .05). Size reduction was even more pronounced in more advanced disease (-78%) than in early-stage disease (-47%). We present preliminary findings using a modified T1-weighted magnetic resonance imaging technique showing stage-dependent substantia nigra signal reduction in Parkinson's disease as a putative marker of neuromelanin loss. Our data suggest that reduction in the size of neuromelanin-rich substantia nigra correlates well with postmortem observations of dopaminergic neuron loss. Further validation of our results could potentially lead to development of a new biomarker of disease progression in Parkinson's disease. © 2011 Movement Disorder Society.
Copyright © 2011 Movement Disorder Society.

Last edited by Conductor71; 04-18-2011 at 02:05 AM. Reason: missing link
Conductor71 is offline   Reply With QuoteReply With Quote
"Thanks for this!" says:
Cando (04-21-2011), soccertese (04-18-2011)